A study to assess the safety, tolerability and pharmacokinetic properties of CEP-37248, a drug for the treatment of autoimmune inflammatory diseases, in healthy men.

Completed

• Conditions: Autoimmune disease; 10003816

• Registration Number: NL-OMON40424
• Lead Sponsor: TEVA Pharma

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 93

Inclusion Criteria

Healthy males
18 -45 years
BMI of 18.0 to 30.0 kg/m2
Weight at least 50 kg

Exclusion Criteria

Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Safety, Tollerability</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>PK</p><br>